{"id":74053,"date":"2026-05-04T00:09:15","date_gmt":"2026-05-04T00:09:15","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/74053\/"},"modified":"2026-05-04T00:09:15","modified_gmt":"2026-05-04T00:09:15","slug":"novo-nordisk-extends-pipeline-with-semaglutide-alcohol-study-and-lx9851-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/74053\/","title":{"rendered":"Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 Trial"},"content":{"rendered":"\n

Never miss an important update on your stock portfolio<\/a> and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.<\/p>\n

Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential treatment for alcohol use disorder, expanding beyond its current uses in diabetes and obesity.<\/p>\n

The company has also begun Phase 1 trials for LX9851, an oral obesity and metabolic disorder drug developed with Lexicon Pharmaceuticals.<\/p>\n

These moves highlight ongoing clinical work in metabolic and related conditions, with implications for future treatment options.<\/p>\n

Novo Nordisk is currently trading at $43.88, with the share price up 6.6% over the past week and 18.7% over the past month. Year to date the stock shows a 16.2% decline, and over the past year it is down 34.5%, despite a 25.1% gain over five years. Against this backdrop, fresh clinical news on semaglutide and LX9851 provides additional context on how the business is evolving beyond current products.<\/p>\n

For investors watching NYSE:NVO, the new semaglutide data in alcohol use disorder and the early stage LX9851 program add more detail to the pipeline story. The key questions now focus on safety, efficacy, and the pace at which these programs progress through clinical stages, which will shape how material they could become for the company\u2019s future revenue mix.<\/p>\n

Stay updated on the most important news stories for Novo Nordisk<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novo Nordisk.<\/p>\n

\"NYSE:NVO<\/a> NYSE:NVO Earnings & Revenue Growth as at May 2026 <\/p>\n

We’ve flagged 3 risks for Novo Nordisk. See which could impact your investment.<\/a><\/p>\n

Quick Assessment <\/p>\n

\u2705 Price vs Analyst Target: At $43.88 versus a consensus target of $48.56, the price sits about 10% below analyst expectations.<\/p>\n

\u2705 Simply Wall St Valuation: Simply Wall St estimates the shares are trading about 60.3% below their calculated fair value.<\/p>\n

\u2705 Recent Momentum: A 30 day return of roughly 18.7% shows strong short term momentum into this pipeline news.<\/p>\n

There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value.<\/a><\/p>\n

Key Considerations <\/p>\n

\ud83d\udcca New semaglutide data in alcohol use disorder and the LX9851 trial extend Novo Nordisk’s reach across metabolic and related conditions, which could influence how durable current earnings appear.<\/p>\n

\ud83d\udcca Keep an eye on clinical readouts, regulatory feedback, and how the P\/E of 12.0 compares with the Pharmaceuticals industry average P\/E of 17.0 as news filters into expectations.<\/p>\n

\u26a0\ufe0f Simply Wall St flags three risks, including a high level of non cash earnings and a dividend that is not well covered by free cash flow, which may matter if trial outcomes lead to higher investment needs.<\/p>\n

Dig Deeper <\/p>\n

For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis<\/a>. Alternatively, you can visit the community page for Novo Nordisk<\/a> to see how other investors believe this latest news will impact the company’s narrative.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NVO<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…\n","protected":false},"author":2,"featured_media":69813,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[39894,26431,39893,272],"class_list":{"0":"post-74053","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-alcohol-use-disorder","9":"tag-lexicon-pharmaceuticals","10":"tag-metabolic-disorder","11":"tag-novo-nordisk"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116513404718176388","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/74053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=74053"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/74053\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/69813"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=74053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=74053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=74053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}